Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Collegium Pharmaceutical Inc    COLL

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
14.73(c) 13.57(c) 13.48(c) 12.73(c) 11.31(c) Last
370 078 403 692 316 018 321 335 990 115 Volume
-4.23% -7.88% -0.66% -5.56% -11.15% Change
More quotes
Financials ($)
Sales 2017 35,7 M
EBIT 2017 -89,2 M
Net income 2017 -85,5 M
Debt 2017 60,0 M
Yield 2017 -
Sales 2018 87,1 M
EBIT 2018 -42,7 M
Net income 2018 -44,7 M
Debt 2018 73,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 11,0x
EV / Sales2018 4,66x
Capitalization 333 M
More Financials
Company
Collegium Pharmaceutical, Inc. is a clinical-stage pharmaceutical company, which focuses on the development of proprietary, late stage pharmaceutical products.These products target market opportunities through formulation based product improvements protected by intellectual property.It builds a... 
Sector
Pharmaceuticals
Calendar
05/16Earnings Release
More about the company
Surperformance© ratings of Collegium Pharmaceutical I
Trading Rating : Investor Rating :
More Ratings
Latest news on COLLEGIUM PHARMACEUTICAL I
03/23 COLLEGIUM PHARMACEUTICAL : Patent Issued for Abuse-Deterrent Pharmaceutical Comp..
03/16 Collegium Announces Scientific Presentation at American Academy of Pain Medic..
03/13 COLLEGIUM PHARMACEUTICAL, INC : Entry into a Material Definitive Agreement, Fina..
03/10 COLLEGIUM PHARMACEUTICAL : Management's Discussion and Analysis of Financial Con..
03/09 COLLEGIUM PHARMACEUTICAL : posts 4Q loss
03/09 COLLEGIUM PHARMACEUTICAL, INC : Results of Operations and Financial Condition, F..
03/09 Collegium Reports Fourth Quarter Financial Results and Provides Corporate Upd..
02/28 Collegium to Host Conference Call to Discuss 2016 Financial Results and Provi..
02/01 Collegium Announces Positive Topline Results of Human Abuse Potential Clinica..
2016 COLLEGIUM PHARMACEUTICAL : The q3 2016 Earnings Estimate for Collegium Pharmaceu..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
Latest Tweets
03/24#DownSideMomentum $COLL COLLEGIUM PHARMACEUTICALS #TradeIdeas via ?  
03/15Collegium Pharmaceutical downgraded by Zacks Investment Research to hold.  
03/15Collegium Pharmaceutical Inc $COLL Downgraded to Hold at Zacks Investment Res.. 
03/13Collegium Pharma inks $60M stock sale deal with Cantor
1
03/09Collegium Pharmaceutical beats by $0.05, misses on revenue  
More tweets
Qtime:21
News from SeekingAlpha
03/24 Midday Gainers / Losers
03/13 Collegium Pharma inks $60M stock sale deal with Cantor
03/09 Collegium Pharmaceutical's (COLL) CEO Mike Heffernan on Q4 2016 Results - Ear..
03/09 Collegium Pharmaceutical beats by $0.05, misses on revenue
02/07 Acura Pharmaceuticals Seeks To Raise $5 Million In Offering
Advertisement
Chart COLLEGIUM PHARMACEUTICAL I
Duration : Period :
Collegium Pharmaceutical I Technical Analysis Chart | COLL | US19459J1043 | 4-Traders
Full-screen chart
Technical analysis trends COLLEGIUM PHARMAC...
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 26,6 $
Spread / Average Target 135%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael Thomas Heffernan Chairman, President & Chief Executive Officer
Paul Brannelly Chief Financial Officer & Executive Vice President
Gino Santini Independent Director
David J. Hirsch Independent Director
John Gordon Freund Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COLLEGIUM PHARMACEUTIC..-27.36%333
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results